Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism
Background Excess alcohol (ethanol, EtOH) consumption is a significant cause of chronic liver disease, accounting for nearly half of the cirrhosis‐associated deaths in the United States. EtOH‐induced liver toxicity is linked to EtOH metabolism and its associated increase in proinflammatory cytokines...
Gespeichert in:
Veröffentlicht in: | Alcoholism, clinical and experimental research clinical and experimental research, 2020-05, Vol.44 (5), p.1046-1060 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1060 |
---|---|
container_issue | 5 |
container_start_page | 1046 |
container_title | Alcoholism, clinical and experimental research |
container_volume | 44 |
creator | Silva, Joshua Yu, Xin Moradian, Renita Folk, Carson Spatz, Maximilian H. Kim, Phoebe Bhatti, Adil A. Davies, Daryl L. Liang, Jing |
description | Background
Excess alcohol (ethanol, EtOH) consumption is a significant cause of chronic liver disease, accounting for nearly half of the cirrhosis‐associated deaths in the United States. EtOH‐induced liver toxicity is linked to EtOH metabolism and its associated increase in proinflammatory cytokines, oxidative stress, and the subsequent activation of Kupffer cells. Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, can reduce EtOH intoxication and potentially protect against chemical‐induced liver injuries. But there remains a paucity of information regarding the effects of DHM on EtOH metabolism and liver protection. As such, the current study tests the hypothesis that DHM supplementation enhances EtOH metabolism and reduces EtOH‐mediated lipid dysregulation, thus promoting hepatocellular health.
Methods
The hepatoprotective effect of DHM (5 and 10 mg/kg; intraperitoneal injection) was evaluated using male C57BL/6J mice and a forced drinking ad libitum EtOH feeding model and HepG2/VL‐17A hepatoblastoma cell models. EtOH‐mediated lipid accumulation and DHM effects against lipid deposits were determined via H&E stains, triglyceride measurements, and intracellular lipid dyes. Protein expression of phosphorylated/total proteins and serum and hepatic cytokines was determined via Western blot and protein array. Total NAD+/NADH Assay of liver homogenates was used to detect NAD + levels.
Results
DHM reduced liver steatosis, liver triglycerides, and liver injury markers in mice chronically fed EtOH. DHM treatment resulted in increased activation of AMPK and downstream targets, carnitine palmitoyltransferase (CPT)‐1a, and acetyl CoA carboxylase (ACC)‐1. DHM induced expression of EtOH‐metabolizing enzymes and reduced EtOH and acetaldehyde concentrations, effects that may be partly explained by changes in NAD+. Furthermore, DHM reduced the expression of proinflammatory cytokines and chemokines in sera and cell models.
Conclusion
In total, these findings support the utility of DHM as a dietary supplement to reduce EtOH‐induced liver injury via changes in lipid metabolism, enhancement of EtOH metabolism, and suppressing inflammation responses to promote liver health.
Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, enhances ethanol metabolism via increased ethanol metabolizing expression and activity. The enhancement of this metabolic activity is likely contributed to by the hepatic increase of nicotinamide adenine dinucleotide (NA |
doi_str_mv | 10.1111/acer.14326 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7211127</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2399969348</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4486-9ad06a6e8773685ad4d17d6e095dc46f3bd88bbf22c3ca8ab9bb39b077e126943</originalsourceid><addsrcrecordid>eNp9kc1qGzEUhUVJaZy0mz5AEGRXGEc_M9JoEwiOmwRcEkq7Fvq5jhXGI0cau_jtK9epSTbRRhfux6eDDkJfKRnTci6MgzSmNWfiAxrRhpOKMCmP0IjQuqkEIe0xOsn5iRBSt0J8QsecMSGbhoyQuw6LrU9xuU3BwRB6_JDiAG7IeFgAnoUNJLwJBk8Wpn-EjAsxC6vg8Q8YjI1dyEtseo-nfQEclGEoQ-xe7T-jj3PTZfjycp-i39-nvya31ez-5m5yNatcXXJVyngijIBWSi7axvjaU-kFENV4V4s5t75trZ0z5rgzrbHKWq4skRIoE6rmp-hy712t7RK8g35IptOrFJYmbXU0Qb_d9GGhH-NGS1a-kckiOH8RpPi8hjzop7hOfcmsGVdKCcXrtlDf9pRLMecE88MLlOhdIXpXiP5XSIHPXmc6oP8bKADdA39CB9t3VPpqMv25l_4Fpl6XoQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399969348</pqid></control><display><type>article</type><title>Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Silva, Joshua ; Yu, Xin ; Moradian, Renita ; Folk, Carson ; Spatz, Maximilian H. ; Kim, Phoebe ; Bhatti, Adil A. ; Davies, Daryl L. ; Liang, Jing</creator><creatorcontrib>Silva, Joshua ; Yu, Xin ; Moradian, Renita ; Folk, Carson ; Spatz, Maximilian H. ; Kim, Phoebe ; Bhatti, Adil A. ; Davies, Daryl L. ; Liang, Jing</creatorcontrib><description>Background
Excess alcohol (ethanol, EtOH) consumption is a significant cause of chronic liver disease, accounting for nearly half of the cirrhosis‐associated deaths in the United States. EtOH‐induced liver toxicity is linked to EtOH metabolism and its associated increase in proinflammatory cytokines, oxidative stress, and the subsequent activation of Kupffer cells. Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, can reduce EtOH intoxication and potentially protect against chemical‐induced liver injuries. But there remains a paucity of information regarding the effects of DHM on EtOH metabolism and liver protection. As such, the current study tests the hypothesis that DHM supplementation enhances EtOH metabolism and reduces EtOH‐mediated lipid dysregulation, thus promoting hepatocellular health.
Methods
The hepatoprotective effect of DHM (5 and 10 mg/kg; intraperitoneal injection) was evaluated using male C57BL/6J mice and a forced drinking ad libitum EtOH feeding model and HepG2/VL‐17A hepatoblastoma cell models. EtOH‐mediated lipid accumulation and DHM effects against lipid deposits were determined via H&E stains, triglyceride measurements, and intracellular lipid dyes. Protein expression of phosphorylated/total proteins and serum and hepatic cytokines was determined via Western blot and protein array. Total NAD+/NADH Assay of liver homogenates was used to detect NAD + levels.
Results
DHM reduced liver steatosis, liver triglycerides, and liver injury markers in mice chronically fed EtOH. DHM treatment resulted in increased activation of AMPK and downstream targets, carnitine palmitoyltransferase (CPT)‐1a, and acetyl CoA carboxylase (ACC)‐1. DHM induced expression of EtOH‐metabolizing enzymes and reduced EtOH and acetaldehyde concentrations, effects that may be partly explained by changes in NAD+. Furthermore, DHM reduced the expression of proinflammatory cytokines and chemokines in sera and cell models.
Conclusion
In total, these findings support the utility of DHM as a dietary supplement to reduce EtOH‐induced liver injury via changes in lipid metabolism, enhancement of EtOH metabolism, and suppressing inflammation responses to promote liver health.
Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, enhances ethanol metabolism via increased ethanol metabolizing expression and activity. The enhancement of this metabolic activity is likely contributed to by the hepatic increase of nicotinamide adenine dinucleotide (NAD), a cofactor required for ethanol metabolism. Additionally, the collective effects of DHM increase antioxidant enzymes and induce AMP‐activated protein kinase (AMPK) metabolic signaling, thereby resulting in reduced steatosis and inflammation. Collectively, DHM shows significant preclinical effects in reducing alcohol‐related liver injury and damage.</description><identifier>ISSN: 0145-6008</identifier><identifier>EISSN: 1530-0277</identifier><identifier>DOI: 10.1111/acer.14326</identifier><identifier>PMID: 32267550</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Acetaldehyde ; Alcohol Liver Damage ; Alcohol use ; Biochemistry, Pharmacology, Physiology and Metabolism ; Carnitine palmitoyltransferase ; Cell activation ; Cell culture ; Chemokines ; Cirrhosis ; Cytokines ; Dietary supplements ; Dihydromyricetin ; Drinking behavior ; Ethanol ; Fatty liver ; Inflammation ; Intoxication ; Kupffer cells ; Lipid metabolism ; Lipids ; Liver ; Liver cirrhosis ; Liver diseases ; Metabolism ; NAD ; NADH ; Original ; Oxidative stress ; Palmitoyltransferase ; Protein arrays ; Steatosis ; Toxicity</subject><ispartof>Alcoholism, clinical and experimental research, 2020-05, Vol.44 (5), p.1046-1060</ispartof><rights>2020 The Authors. published by Wiley Periodicals LLC on behalf of Research Society on Alcoholism</rights><rights>2020 The Authors. Alcoholism: Clinical & Experimental Research published by Wiley Periodicals LLC on behalf of Research Society on Alcoholism.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4486-9ad06a6e8773685ad4d17d6e095dc46f3bd88bbf22c3ca8ab9bb39b077e126943</citedby><cites>FETCH-LOGICAL-c4486-9ad06a6e8773685ad4d17d6e095dc46f3bd88bbf22c3ca8ab9bb39b077e126943</cites><orcidid>0000-0002-2010-729X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Facer.14326$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Facer.14326$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32267550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Silva, Joshua</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><creatorcontrib>Moradian, Renita</creatorcontrib><creatorcontrib>Folk, Carson</creatorcontrib><creatorcontrib>Spatz, Maximilian H.</creatorcontrib><creatorcontrib>Kim, Phoebe</creatorcontrib><creatorcontrib>Bhatti, Adil A.</creatorcontrib><creatorcontrib>Davies, Daryl L.</creatorcontrib><creatorcontrib>Liang, Jing</creatorcontrib><title>Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism</title><title>Alcoholism, clinical and experimental research</title><addtitle>Alcohol Clin Exp Res</addtitle><description>Background
Excess alcohol (ethanol, EtOH) consumption is a significant cause of chronic liver disease, accounting for nearly half of the cirrhosis‐associated deaths in the United States. EtOH‐induced liver toxicity is linked to EtOH metabolism and its associated increase in proinflammatory cytokines, oxidative stress, and the subsequent activation of Kupffer cells. Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, can reduce EtOH intoxication and potentially protect against chemical‐induced liver injuries. But there remains a paucity of information regarding the effects of DHM on EtOH metabolism and liver protection. As such, the current study tests the hypothesis that DHM supplementation enhances EtOH metabolism and reduces EtOH‐mediated lipid dysregulation, thus promoting hepatocellular health.
Methods
The hepatoprotective effect of DHM (5 and 10 mg/kg; intraperitoneal injection) was evaluated using male C57BL/6J mice and a forced drinking ad libitum EtOH feeding model and HepG2/VL‐17A hepatoblastoma cell models. EtOH‐mediated lipid accumulation and DHM effects against lipid deposits were determined via H&E stains, triglyceride measurements, and intracellular lipid dyes. Protein expression of phosphorylated/total proteins and serum and hepatic cytokines was determined via Western blot and protein array. Total NAD+/NADH Assay of liver homogenates was used to detect NAD + levels.
Results
DHM reduced liver steatosis, liver triglycerides, and liver injury markers in mice chronically fed EtOH. DHM treatment resulted in increased activation of AMPK and downstream targets, carnitine palmitoyltransferase (CPT)‐1a, and acetyl CoA carboxylase (ACC)‐1. DHM induced expression of EtOH‐metabolizing enzymes and reduced EtOH and acetaldehyde concentrations, effects that may be partly explained by changes in NAD+. Furthermore, DHM reduced the expression of proinflammatory cytokines and chemokines in sera and cell models.
Conclusion
In total, these findings support the utility of DHM as a dietary supplement to reduce EtOH‐induced liver injury via changes in lipid metabolism, enhancement of EtOH metabolism, and suppressing inflammation responses to promote liver health.
Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, enhances ethanol metabolism via increased ethanol metabolizing expression and activity. The enhancement of this metabolic activity is likely contributed to by the hepatic increase of nicotinamide adenine dinucleotide (NAD), a cofactor required for ethanol metabolism. Additionally, the collective effects of DHM increase antioxidant enzymes and induce AMP‐activated protein kinase (AMPK) metabolic signaling, thereby resulting in reduced steatosis and inflammation. Collectively, DHM shows significant preclinical effects in reducing alcohol‐related liver injury and damage.</description><subject>Acetaldehyde</subject><subject>Alcohol Liver Damage</subject><subject>Alcohol use</subject><subject>Biochemistry, Pharmacology, Physiology and Metabolism</subject><subject>Carnitine palmitoyltransferase</subject><subject>Cell activation</subject><subject>Cell culture</subject><subject>Chemokines</subject><subject>Cirrhosis</subject><subject>Cytokines</subject><subject>Dietary supplements</subject><subject>Dihydromyricetin</subject><subject>Drinking behavior</subject><subject>Ethanol</subject><subject>Fatty liver</subject><subject>Inflammation</subject><subject>Intoxication</subject><subject>Kupffer cells</subject><subject>Lipid metabolism</subject><subject>Lipids</subject><subject>Liver</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Metabolism</subject><subject>NAD</subject><subject>NADH</subject><subject>Original</subject><subject>Oxidative stress</subject><subject>Palmitoyltransferase</subject><subject>Protein arrays</subject><subject>Steatosis</subject><subject>Toxicity</subject><issn>0145-6008</issn><issn>1530-0277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp9kc1qGzEUhUVJaZy0mz5AEGRXGEc_M9JoEwiOmwRcEkq7Fvq5jhXGI0cau_jtK9epSTbRRhfux6eDDkJfKRnTci6MgzSmNWfiAxrRhpOKMCmP0IjQuqkEIe0xOsn5iRBSt0J8QsecMSGbhoyQuw6LrU9xuU3BwRB6_JDiAG7IeFgAnoUNJLwJBk8Wpn-EjAsxC6vg8Q8YjI1dyEtseo-nfQEclGEoQ-xe7T-jj3PTZfjycp-i39-nvya31ez-5m5yNatcXXJVyngijIBWSi7axvjaU-kFENV4V4s5t75trZ0z5rgzrbHKWq4skRIoE6rmp-hy712t7RK8g35IptOrFJYmbXU0Qb_d9GGhH-NGS1a-kckiOH8RpPi8hjzop7hOfcmsGVdKCcXrtlDf9pRLMecE88MLlOhdIXpXiP5XSIHPXmc6oP8bKADdA39CB9t3VPpqMv25l_4Fpl6XoQ</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Silva, Joshua</creator><creator>Yu, Xin</creator><creator>Moradian, Renita</creator><creator>Folk, Carson</creator><creator>Spatz, Maximilian H.</creator><creator>Kim, Phoebe</creator><creator>Bhatti, Adil A.</creator><creator>Davies, Daryl L.</creator><creator>Liang, Jing</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K7.</scope><scope>K9.</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2010-729X</orcidid></search><sort><creationdate>202005</creationdate><title>Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism</title><author>Silva, Joshua ; Yu, Xin ; Moradian, Renita ; Folk, Carson ; Spatz, Maximilian H. ; Kim, Phoebe ; Bhatti, Adil A. ; Davies, Daryl L. ; Liang, Jing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4486-9ad06a6e8773685ad4d17d6e095dc46f3bd88bbf22c3ca8ab9bb39b077e126943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acetaldehyde</topic><topic>Alcohol Liver Damage</topic><topic>Alcohol use</topic><topic>Biochemistry, Pharmacology, Physiology and Metabolism</topic><topic>Carnitine palmitoyltransferase</topic><topic>Cell activation</topic><topic>Cell culture</topic><topic>Chemokines</topic><topic>Cirrhosis</topic><topic>Cytokines</topic><topic>Dietary supplements</topic><topic>Dihydromyricetin</topic><topic>Drinking behavior</topic><topic>Ethanol</topic><topic>Fatty liver</topic><topic>Inflammation</topic><topic>Intoxication</topic><topic>Kupffer cells</topic><topic>Lipid metabolism</topic><topic>Lipids</topic><topic>Liver</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Metabolism</topic><topic>NAD</topic><topic>NADH</topic><topic>Original</topic><topic>Oxidative stress</topic><topic>Palmitoyltransferase</topic><topic>Protein arrays</topic><topic>Steatosis</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Silva, Joshua</creatorcontrib><creatorcontrib>Yu, Xin</creatorcontrib><creatorcontrib>Moradian, Renita</creatorcontrib><creatorcontrib>Folk, Carson</creatorcontrib><creatorcontrib>Spatz, Maximilian H.</creatorcontrib><creatorcontrib>Kim, Phoebe</creatorcontrib><creatorcontrib>Bhatti, Adil A.</creatorcontrib><creatorcontrib>Davies, Daryl L.</creatorcontrib><creatorcontrib>Liang, Jing</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Alcoholism, clinical and experimental research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Silva, Joshua</au><au>Yu, Xin</au><au>Moradian, Renita</au><au>Folk, Carson</au><au>Spatz, Maximilian H.</au><au>Kim, Phoebe</au><au>Bhatti, Adil A.</au><au>Davies, Daryl L.</au><au>Liang, Jing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism</atitle><jtitle>Alcoholism, clinical and experimental research</jtitle><addtitle>Alcohol Clin Exp Res</addtitle><date>2020-05</date><risdate>2020</risdate><volume>44</volume><issue>5</issue><spage>1046</spage><epage>1060</epage><pages>1046-1060</pages><issn>0145-6008</issn><eissn>1530-0277</eissn><abstract>Background
Excess alcohol (ethanol, EtOH) consumption is a significant cause of chronic liver disease, accounting for nearly half of the cirrhosis‐associated deaths in the United States. EtOH‐induced liver toxicity is linked to EtOH metabolism and its associated increase in proinflammatory cytokines, oxidative stress, and the subsequent activation of Kupffer cells. Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, can reduce EtOH intoxication and potentially protect against chemical‐induced liver injuries. But there remains a paucity of information regarding the effects of DHM on EtOH metabolism and liver protection. As such, the current study tests the hypothesis that DHM supplementation enhances EtOH metabolism and reduces EtOH‐mediated lipid dysregulation, thus promoting hepatocellular health.
Methods
The hepatoprotective effect of DHM (5 and 10 mg/kg; intraperitoneal injection) was evaluated using male C57BL/6J mice and a forced drinking ad libitum EtOH feeding model and HepG2/VL‐17A hepatoblastoma cell models. EtOH‐mediated lipid accumulation and DHM effects against lipid deposits were determined via H&E stains, triglyceride measurements, and intracellular lipid dyes. Protein expression of phosphorylated/total proteins and serum and hepatic cytokines was determined via Western blot and protein array. Total NAD+/NADH Assay of liver homogenates was used to detect NAD + levels.
Results
DHM reduced liver steatosis, liver triglycerides, and liver injury markers in mice chronically fed EtOH. DHM treatment resulted in increased activation of AMPK and downstream targets, carnitine palmitoyltransferase (CPT)‐1a, and acetyl CoA carboxylase (ACC)‐1. DHM induced expression of EtOH‐metabolizing enzymes and reduced EtOH and acetaldehyde concentrations, effects that may be partly explained by changes in NAD+. Furthermore, DHM reduced the expression of proinflammatory cytokines and chemokines in sera and cell models.
Conclusion
In total, these findings support the utility of DHM as a dietary supplement to reduce EtOH‐induced liver injury via changes in lipid metabolism, enhancement of EtOH metabolism, and suppressing inflammation responses to promote liver health.
Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, enhances ethanol metabolism via increased ethanol metabolizing expression and activity. The enhancement of this metabolic activity is likely contributed to by the hepatic increase of nicotinamide adenine dinucleotide (NAD), a cofactor required for ethanol metabolism. Additionally, the collective effects of DHM increase antioxidant enzymes and induce AMP‐activated protein kinase (AMPK) metabolic signaling, thereby resulting in reduced steatosis and inflammation. Collectively, DHM shows significant preclinical effects in reducing alcohol‐related liver injury and damage.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32267550</pmid><doi>10.1111/acer.14326</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-2010-729X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0145-6008 |
ispartof | Alcoholism, clinical and experimental research, 2020-05, Vol.44 (5), p.1046-1060 |
issn | 0145-6008 1530-0277 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7211127 |
source | Wiley Online Library Journals Frontfile Complete |
subjects | Acetaldehyde Alcohol Liver Damage Alcohol use Biochemistry, Pharmacology, Physiology and Metabolism Carnitine palmitoyltransferase Cell activation Cell culture Chemokines Cirrhosis Cytokines Dietary supplements Dihydromyricetin Drinking behavior Ethanol Fatty liver Inflammation Intoxication Kupffer cells Lipid metabolism Lipids Liver Liver cirrhosis Liver diseases Metabolism NAD NADH Original Oxidative stress Palmitoyltransferase Protein arrays Steatosis Toxicity |
title | Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A10%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dihydromyricetin%20Protects%20the%20Liver%20via%20Changes%20in%20Lipid%20Metabolism%20and%20Enhanced%20Ethanol%20Metabolism&rft.jtitle=Alcoholism,%20clinical%20and%20experimental%20research&rft.au=Silva,%20Joshua&rft.date=2020-05&rft.volume=44&rft.issue=5&rft.spage=1046&rft.epage=1060&rft.pages=1046-1060&rft.issn=0145-6008&rft.eissn=1530-0277&rft_id=info:doi/10.1111/acer.14326&rft_dat=%3Cproquest_pubme%3E2399969348%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2399969348&rft_id=info:pmid/32267550&rfr_iscdi=true |